SCHEMBL733912

SCHEMBL733912

CC(C)(C)c1ccc(S(=O)(=O)N2CCN(Cc3ccccc3)CC2CO)cc1

nearest known ligand 0.60

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 4/20 0.60
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
MMP1 P03956 2/20 0.50
MMP9 P14780 2/20 0.50
MMP13 P45452 2/20 0.50
MMP3 P08254 1/20 0.50
MMP7 P09237 1/20 0.50
CA1 P00915 4/20 0.47
CA2 P00918 4/20 0.47
CA4 P22748 4/20 0.47
CA9 Q16790 4/20 0.47
SIGMAR1 Q99720 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17069873 0.78 POLB (0.68) HSD11B1MEN1KMT2A
SCHEMBL12169368 0.75 BRD4 (0.63) HSD11B1MEN1KMT2A
SCHEMBL733595 0.75 ALDH1A1 (0.49) HSD11B1MEN1KMT2AMMP1MMP9
SCHEMBL12406627 0.74 BRD4 (0.58) HSD11B1MEN1KMT2A
SCHEMBL29277635 0.72 SIGMAR1 (0.56) MEN1KMT2ASIGMAR1
SCHEMBL734974 0.72 HSD11B1 (0.48) HSD11B1MEN1KMT2AMMP1MMP9
SCHEMBL3611602 0.72 HSD11B1 (0.74) HSD11B1MEN1KMT2A
SCHEMBL16433234 0.72 PTGDR2 (0.45) HSD11B1MMP1MMP9MMP13MMP3
SCHEMBL16433229 0.72 PTGDR2 (0.45) HSD11B1MMP1MMP9MMP13MMP3
SCHEMBL6793495 0.72 MMP1 (0.55) KMT2AMMP1MMP9MMP13MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138190-B2 Diaza heterocyclic amide compounds and their uses AMGEN INC. (US) 2012-03-20 US disclosed
US-8138190-B2 Diaza heterocyclic amide compounds and their uses AMGEN INC. (US) 2012-03-20 US disclosed
US-8138190-B2 Diaza heterocyclic amide compounds and their uses AMGEN INC. (US) 2012-03-20 US disclosed
US-7825122-B2 Diaza heterocyclic sulfonamide derivatives and their uses AMGEN INC. (US) 2010-11-02 US disclosed
US-7825122-B2 Diaza heterocyclic sulfonamide derivatives and their uses AMGEN INC. (US) 2010-11-02 US disclosed
US-7825122-B2 Diaza heterocyclic sulfonamide derivatives and their uses AMGEN INC. (US) 2010-11-02 US disclosed
US-20090176768-A1 DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES AMGEN INC. 2009-07-09 US disclosed
US-20090176768-A1 DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES AMGEN INC. 2009-07-09 US disclosed
US-20090176768-A1 DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES AMGEN INC. 2009-07-09 US disclosed
US-7524848-B2 Diaza heterocyclic amide compounds and their uses AMGEN INC. (US) 2009-04-28 US disclosed
US-7524848-B2 Diaza heterocyclic amide compounds and their uses AMGEN INC. (US) 2009-04-28 US disclosed
US-7524848-B2 Diaza heterocyclic amide compounds and their uses AMGEN INC. (US) 2009-04-28 US disclosed
US-20070249626-A1 Diaza heterocyclic amide compounds and their uses AMGEN INC. 2007-10-25 US disclosed
US-20070249626-A1 Diaza heterocyclic amide compounds and their uses AMGEN INC. 2007-10-25 US disclosed
US-20070249626-A1 Diaza heterocyclic amide compounds and their uses AMGEN INC. 2007-10-25 US disclosed
WO-2007111921-A1 1-PHENYLSULFONYL-DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES AS MODULATORS OF HYDROXSTEROID DEHYDROGENASES AMGEN INC. (US) 2007-10-04 WO disclosed
US-20070173494-A1 Diaza heterocyclic sulfonamide derivatives and their uses AMGEN INC. 2007-07-26 US disclosed
US-20070173494-A1 Diaza heterocyclic sulfonamide derivatives and their uses AMGEN INC. 2007-07-26 US disclosed
US-20070173494-A1 Diaza heterocyclic sulfonamide derivatives and their uses AMGEN INC. 2007-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173494-A1 Diaza heterocyclic sulfonamide derivatives and their uses GLP1R, GPR119, INSR HSD11B1 685/4885MEN1 1597/4885KMT2A 821/4885
US-20090176768-A1 DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES GPR119, GLP1R, INSR HSD11B1 2477/4885MEN1 989/4885KMT2A 531/4885
US-20070249626-A1 Diaza heterocyclic amide compounds and their uses GPR119, GLP1R, INSR HSD11B1 2477/4885MEN1 989/4885KMT2A 531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.